Iranian Red Crescent Medical Journal

Published by: Kowsar

The Effect of 17α-Hydroxyprogesterone Caproate on Prevention of Preterm Labor in High-Risk Pregnant Women

Shole Shahgheibi 1 , Nazli Hamrah 1 , * , Nasrin Soofizadeh 1 , Aidin Mojtahedzadeh 2 , Fariba Seyedoshohadaei 1 , Masomeh Rezaie 1 and Ghobad Moradi 3
Authors Information
1 Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
2 Department of Pathology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
3 Department of Epidemiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: February 01, 2016, 18 (2); e26150
  • Published Online: February 20, 2016
  • Article Type: Research Article
  • Received: January 6, 2015
  • Revised: June 16, 2015
  • Accepted: January 2, 2016
  • DOI: 10.5812/ircmj.26150

To Cite: Shahgheibi S, Hamrah N, Soofizadeh N, Mojtahedzadeh A, Seyedoshohadaei F, et al. The Effect of 17α-Hydroxyprogesterone Caproate on Prevention of Preterm Labor in High-Risk Pregnant Women, Iran Red Crescent Med J. 2016 ; 18(2):e26150. doi: 10.5812/ircmj.26150.

Abstract
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Cunningham FG, Leveno KJ, Bloom SL, Hauth J, Gilstrap L, Wenstrom K. Williams obstetrics. 22nd. 2005; 987: 804-17
  • 2. Vidaeff AC, Ramin SM. Management strategies for the prevention of preterm birth. Part I: Update on progesterone supplementation. Curr Opin Obstet Gynecol. 2009; 21(6): 480-4[DOI][PubMed]
  • 3. Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev. 2012; 12[DOI][PubMed]
  • 4. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005; 193(3 Pt 2): 1127-31[DOI][PubMed]
  • 5. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol. 2003; 102(3): 488-92[PubMed]
  • 6. Petrou S, Mehta Z, Hockley C, Cook-Mozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital inpatient admissions and costs during the first 5 years of life. Pediatrics. 2003; 112(6 Pt 1): 1290-7[PubMed]
  • 7. Bloom SL, Yost NP, McIntire DD, Leveno KJ. Recurrence of preterm birth in singleton and twin pregnancies. Obstet Gynecol. 2001; 98(3): 379-85[PubMed]
  • 8. Rust OA, Bofill JA, Arriola RM, Andrew ME, Morrison JC. The clinical efficacy of oral tocolytic therapy. Am J Obstetr Gynecol. 1996; 175(4): 838-42[DOI]
  • 9. Levine L. Habitual abortion. A controlled clinical study of presentational therapy. West J Surg. 1964; 72: 30-6
  • 10. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Lib. 2004;
  • 11. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999; 14(8): 1944-8[PubMed]
  • 12. Gallagher K. Progesterone for preventing preterm labor and delivery. Am College Obstetricians Gynecol Obstetr Gynecol. 2003; 102: 1115-6
  • 13. Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyl progesterone treatment during pregnancy. Congenital Anomalies. 2006; 46: 194-8
  • 14. Danforth DN, Gibbs RS. Danforth's obstetrics and gynecology. 2008;
  • 15. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348(24): 2379-85[DOI][PubMed]
  • 16. Pessel C, Moni S, Zork N, Brubaker S, Vink J, Fuchs K, et al. The effect of intramuscular progesterone on the rate of cervical shortening. Am J Obstet Gynecol. 2013; 209(3): 269 e1-7[DOI][PubMed]
  • 17. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening G. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007; 357(5): 462-9[DOI][PubMed]
  • 18. Fontenot HB, Fantasia HC. Vaginal progesterone to prevent preterm birth in high-risk women. Nurs Womens Health. 2012; 16(3): 237-41[DOI][PubMed]
  • 19. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007; 30(5): 687-96[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments